A 40-person phase I trial found liver fat fell by up to 80.3% after one CIDEBsiRNA dose, but larger studies must test clinical benefits and risks.
Browsing Category
Medical Conditions & Diagnostic Testing
514 posts
Another Option For Rare Benign Soft-Tissue Tumor Wins FDA Approval
The FDA approved pimicotinib for symptomatic tenosynovial giant cell tumors when surgery could cause serious harm or worsen function.
Why Not Sirolimus For Active Lupus?
A 145-patient trial found better lupus response with sirolimus than placebo, but infections, blood-test abnormalities and longer-term safety remain concerns.
Ditching Primary Prevention Statins In Old Age? Technically ‘Safe’ With Caveats
In STREAM, stopping primary-prevention statins in adults 70 and older met a two-year non-inferiority test, but cardiovascular events were numerically higher.
Kidney Care Trial Challenges Default Dialysis Planning For Older Adults With Frailty
A U.K. randomized trial found similar combined survival and quality-of-life outcomes for older, frail kidney patients preparing for dialysis or conservative care.
Elizabeth Holmes Documentary: Doctors Weigh In
MedPage Today discusses two doctors’ commentaries on a documentary about Elizabeth Holmes, including its portrayal of her psychology and relationship.
Scientists Solve 30-Year-old Mystery And Discover A Hidden Defense Against Inflammation
MSK researchers identified DHRS7, an enzyme in the 5-oxoETE pathway, and found evidence it may help limit inflammatory damage.
SGMC Health Urges Community To Take Precautions As Flu Cases Rise
SGMC Health reports local flu cases significantly above last year’s level and urges vaccination, hygiene and appropriate care-seeking.
Abdakibart Shows Strong Early Efficacy In Hidradenitis Suppurativa
In the 240-patient LOTUS phase II trial, about 43% of abdakibart-treated patients reached HiSCR75 at week 16, versus 25% on placebo.
Cancer Vaccines Show Promise. But We Have More Work To Do.
A phase III melanoma trial found fewer recurrences with an individualized mRNA vaccine plus pembrolizumab, but survival benefit and broader use remain unproven.